Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults-MedSci.cn

Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults

Li, C; Liu, HY; Liao, YX; Zhu, Y; Tian, JY; Wang, X; Hu, ZQ; Zhan, YX; Li, XB; Liang, XT; He, J; Li, YM; Shang, DW; Zheng, QS; Wang, TH; Song, HF; Fang, Y

Wang, TH (通讯作者)，Guangzhou Med Univ, Dept Pharm, Key Lab Biol Targeting Diag Therapy & Rehabil Guan, Affiliated Hosp 5, Guangzhou, Peoples R China.;Song, HF (通讯作者)，Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing, Peoples R China.;Fang, Y (通讯作者)，Peking Univ Peoples Hosp, Clin Trial Inst Res Ward, Beijing, Peoples R China.

BIODRUGS, 2023; 37 (5): 721

Abstract

BackgroundGB223 is a novel, fully-humanized monoclonal antibody against the receptor activator of nuclear factor-kappa B ligand (RANKL). In this phase......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults

科室

工具

服务